Fully Integrated AAV Engineering and Gene Therapy Company
We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications.
Current gene therapy approaches have shown dramatic efficacy in several rare diseases but are hindered by imprecise targeting. The inability to selectively transduce specific cells and tissues effectively drives administration of higher doses and resulting safety liabilities. We are addressing these concerns with our proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the disease organ while limiting transduction of tissues and cells not relevant to the target disease.
Through our next-generation AAV platform combined with cargo development and state-of-the-art manufacturing, we are tackling monogenetic and sporadic CNS and non-CNS disorders that have previously been challenging to address.
New 15,000 square-foot facility in Thousand Oaks will enable industry leading end-to-end gene therapy manufacturing capability THOUSAND OAKS, Calif., July 22, 2021 – Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, today announced the opening of … Read MoreRead More
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia
Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases ZUG, Switzerland, CAMBRIDGE, Mass., and THOUSAND OAKS, Calif. – June 15, 2021 — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Capsida Biotherapeutics Inc., a biotechnology company dedicated to developing … Read MoreRead More
Capsida Biotherapeutics Inc., a biotechnology company creating a new class of targeted gene therapies using its next-generation adeno-associated virus (AAV) engineering and cargo development platform, today announced the appointment of Swati Tole, M.D., as the Company’s first chief medical officer.Read More